CD274 and head and neck squamous cell carcinoma: The US FDA has approved three PD-L1 inhibitors namely Atezolimumab, Durvalumab and Avelumab that have been used in some solid tumours, including NSCLC, HNSCC, melanoma, and MCC [34].